---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-005338"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T00:58:10.555548+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences licenses Yale simufilam patent for TSC-related seizures; up to $4.5M milestones

## Summary
- Exclusive worldwide license to issued US method of treatment patent (US 12,186,307) for simufilam in TSC-related epilepsy and other indications.
- Financial terms: nominal upfront, up to $4.5M in clinical/regulatory/commercial milestones, tiered low-to-mid single-digit % royalties on net sales.
- Based on Yale research (Bordey et al., Science Translational Medicine 2020) showing simufilam reduced seizure frequency in an animal model.
- Cassava to prioritize initial development on TSC-related seizures and plans preclinical studies with the TSC Alliance.

## SEC filing metadata
- accession: 0001437749-25-005338
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774925005338/0001437749-25-005338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774925005338/sava20250224_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-005338
- JSON: https://secwatch.observer/filing/0001437749-25-005338.json
- Plain text: https://secwatch.observer/filing/0001437749-25-005338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.